{"id":"placebo-to-evolocumab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2364655","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PCSK9, evolocumab increases the number of LDL receptors on the liver, allowing for more LDL to be removed from the blood. This results in a decrease in LDL cholesterol levels, which can help to reduce the risk of cardiovascular events.","oneSentence":"Evolocumab works by binding to PCSK9, a protein that regulates cholesterol levels in the blood, thereby increasing the levels of HDL and reducing the levels of LDL.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:34.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"},{"name":"Heterozygous familial hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT06081153","phase":"EARLY_PHASE1","title":"Mechanistic Clinical Trial of PCSK9 Inhibition for AAA","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-07-01","conditions":"Abdominal Aortic Aneurysm","enrollment":44},{"nctId":"NCT07286110","phase":"PHASE1","title":"Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12-30","conditions":"Moyamoya Disease, Moyamoya Syndrome","enrollment":66},{"nctId":"NCT03872401","phase":"PHASE3","title":"Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-06-11","conditions":"Coronary Heart Disease (CHD)","enrollment":12301},{"nctId":"NCT03900026","phase":"PHASE4","title":"Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2019-05-30","conditions":"Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion","enrollment":782},{"nctId":"NCT04992065","phase":"PHASE2","title":"A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-08-03","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":267},{"nctId":"NCT04141579","phase":"NA","title":"Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-11-10","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery","enrollment":150},{"nctId":"NCT01764633","phase":"PHASE3","title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-02-08","conditions":"Dyslipidemia","enrollment":27564},{"nctId":"NCT04189484","phase":"PHASE1","title":"Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-01-07","conditions":"Healthy Subjects, Pharmacokinetics, Pharmacodynamics","enrollment":72},{"nctId":"NCT03734211","phase":"PHASE3","title":"Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients","status":"COMPLETED","sponsor":"Lars Gullestad","startDate":"2019-06-10","conditions":"Cardiac Allograft Vasculopathy","enrollment":130},{"nctId":"NCT03626831","phase":"PHASE4","title":"Effect of Evolocumab on Vascular Function","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2019-04-04","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":105},{"nctId":"NCT03433755","phase":"PHASE3","title":"Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-05-09","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":259},{"nctId":"NCT01380730","phase":"PHASE2","title":"LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-01","conditions":"Hyperlipidemia","enrollment":631},{"nctId":"NCT01375751","phase":"PHASE2","title":"Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-08-02","conditions":"Hypercholesterolemia, Familial","enrollment":168},{"nctId":"NCT01375777","phase":"PHASE2","title":"Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-06","conditions":"Hyperlipidemia","enrollment":411},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01763827","phase":"PHASE3","title":"Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-21","conditions":"Hyperlipidemia","enrollment":615},{"nctId":"NCT02392559","phase":"PHASE3","title":"Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-03-24","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":158},{"nctId":"NCT01375764","phase":"PHASE2","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-28","conditions":"Hyperlipidemia","enrollment":160},{"nctId":"NCT02729025","phase":"PHASE3","title":"Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-04-14","conditions":"Subjects With Hyperlipidemia, Dyslipidemia","enrollment":129},{"nctId":"NCT04510844","phase":"PHASE4","title":"Evolocumab In Advanced Chronic Kidney Disease Trial","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2021-03-01","conditions":"Chronic Kidney Diseases, High Cholesterol","enrollment":""},{"nctId":"NCT01516879","phase":"PHASE3","title":"Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-01-05","conditions":"Hypercholesterolemia","enrollment":905},{"nctId":"NCT02833844","phase":"PHASE3","title":"Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-05-22","conditions":"Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection","enrollment":467},{"nctId":"NCT03570697","phase":"PHASE3","title":"Imaging of Coronary Plaques in Participants Treated With Evolocumab","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-11-19","conditions":"Coronary Artery Disease (CAD)","enrollment":164},{"nctId":"NCT04539223","phase":"PHASE4","title":"A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy","status":"UNKNOWN","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2020-08-28","conditions":"Carotid Artery Stenosis, Asymptomatic Carotid Artery Stenosis","enrollment":60},{"nctId":"NCT03096288","phase":"PHASE4","title":"Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-10-03","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":259},{"nctId":"NCT04659525","phase":"PHASE4","title":"Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia","status":"UNKNOWN","sponsor":"Policlinico Casilino ASL RMB","startDate":"2020-11-01","conditions":"Hypercholesterolemia, CKD Stage 5, Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":50},{"nctId":"NCT02634580","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-27","conditions":"Hypercholesterolemia","enrollment":61},{"nctId":"NCT01763905","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-24","conditions":"Hyperlipidemia","enrollment":307},{"nctId":"NCT04397653","phase":"PHASE4","title":"Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients","status":"UNKNOWN","sponsor":"Policlinico Casilino ASL RMB","startDate":"2020-05-04","conditions":"Hypercholesterolemia, Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":50},{"nctId":"NCT03193047","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-04-07","conditions":"Hypercholesterolemia","enrollment":59},{"nctId":"NCT04306471","phase":"PHASE4","title":"Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)","status":"UNKNOWN","sponsor":"Leonardo Clavijo","startDate":"2020-02-24","conditions":"Critical Limb Ischemia","enrollment":32},{"nctId":"NCT04306081","phase":"PHASE4","title":"Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease","status":"UNKNOWN","sponsor":"Leonardo Clavijo","startDate":"2017-12-14","conditions":"Peripheral Arterial Disease","enrollment":86},{"nctId":"NCT01763918","phase":"PHASE3","title":"Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-02-07","conditions":"Hyperlipidemia","enrollment":331},{"nctId":"NCT01813422","phase":"PHASE3","title":"GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-04-18","conditions":"Hypercholesterolemia","enrollment":970},{"nctId":"NCT03811223","phase":"PHASE4","title":"Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2019-08","conditions":"Familial Dysbetalipoproteinemia, Hyperlipoproteinemia Type III","enrollment":30},{"nctId":"NCT02662569","phase":"PHASE3","title":"Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-04-14","conditions":"Diabetes, Hyperlipidemia, Mixed Dyslipidemia","enrollment":986},{"nctId":"NCT01588496","phase":"PHASE2, PHASE3","title":"Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-04-05","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":58},{"nctId":"NCT01984424","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-12-10","conditions":"Hyperlipidemia","enrollment":511},{"nctId":"NCT01652703","phase":"PHASE2","title":"A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-07-10","conditions":"Hypercholesterolemia and High Risk for Cardiovascular Events","enrollment":310},{"nctId":"NCT01133522","phase":"PHASE1","title":"Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-06-01","conditions":"Hyperlipidemia","enrollment":60},{"nctId":"NCT02189837","phase":"PHASE3","title":"Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-07-08","conditions":"Primary Hyperlipidemia and Mixed Dyslipidemia","enrollment":89},{"nctId":"NCT02739984","phase":"PHASE3","title":"Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-05-17","conditions":"Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes","enrollment":424},{"nctId":"NCT02207634","phase":"PHASE3","title":"Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-09-10","conditions":"Dyslipidemia","enrollment":1974},{"nctId":"NCT01953328","phase":"PHASE3","title":"Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-10","conditions":"Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events","enrollment":409}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Evolocumab","genericName":"Placebo to Evolocumab","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Evolocumab works by binding to PCSK9, a protein that regulates cholesterol levels in the blood, thereby increasing the levels of HDL and reducing the levels of LDL. Used for Hypercholesterolemia, Heterozygous familial hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":10,"withResults":10},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}